tiprankstipranks
Trending News
More News >

Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies

Story Highlights
Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies

Confident Investing Starts Here:

Camurus AB ( (SE:CAMX) ) has issued an announcement.

Camurus has entered a collaboration and license agreement with Eli Lilly, granting Lilly exclusive rights to develop and commercialize long-acting incretin products for cardiometabolic health using Camurus’ FluidCrystal technology. This partnership could bring Camurus up to $870 million in milestone payments and royalties, enhancing its market presence in the rapidly expanding field of metabolic diseases while allowing it to maintain its focus on CNS and rare diseases.

The most recent analyst rating on (SE:CAMX) stock is a Buy with a SEK710.00 price target. To see the full list of analyst forecasts on Camurus AB stock, see the SE:CAMX Stock Forecast page.

More about Camurus AB

Camurus is an international, science-led biopharmaceutical company headquartered in Lund, Sweden, focused on developing and commercializing innovative, long-acting medicines for severe and chronic diseases. The company’s proprietary FluidCrystal technology is central to its R&D efforts, with a pipeline addressing dependence, pain, cancer, and endocrine diseases. Camurus operates across Europe, the US, and Australia, and is listed on Nasdaq Stockholm.

Average Trading Volume: 98,323

Current Market Cap: SEK30.35B

Learn more about CAMX stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App